CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Alkermes Settles LYBALVI Patent Litigation With Teva

By Public Technologies
  • Alkermes settled patent litigation with Teva on November 6, 2026, covering all dosage strengths of Lybalvi.
  • The agreement grants Teva a non-exclusive, royalty-free license to sell its products in the United States beginning November 12, 2039.
  • Pediatric exclusivity would delay entry to May 12, 2040; earlier entry is possible under certain circumstances.
  • The parties filed to dismiss the litigation with prejudice on November 9, 2026.
  • The settlement is subject to review by the U.S. Federal Trade Commission and Department of Justice.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alkermes plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-456888), on November 12, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk